Home » Topics » Regulatory » NMPA

NMPA
RSS

Chinese authorities approve clinical trials of ZKAB-001

Jan. 30, 2018

China FDA accepts IND for Ascentage's IAP inhibitor

Jan. 9, 2018

CFDA designates lenvatinib for priority review and approval for HCC

Dec. 28, 2017

Clover Biopharmaceuticals receives approval to initiate clinical trials of SCB-808 in China

Dec. 28, 2017

Ebola vaccine approved in China

Oct. 26, 2017

Fosun Pharma reports Chinese IND application for FCN-437c

July 19, 2017

CStone cleared to begin clinical trials of CS-1001 in China

July 18, 2017

China FDA accepts fruquintinib NDA for advanced colorectal cancer

June 12, 2017

Tagrisso approved in China for NSCLC

March 27, 2017

WuXi-MedImmune cleared to conduct phase I studies of WBP-216 in China

Jan. 19, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 16, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...